Pharmacokinetics, distribution, metabolism, and excretion of BPC-157 in animals
Cooke P, Snider R
Zvintzou E, Skroubis G, Chroni A, Petropoulou PI, Gkolfinopoulou C, Sakellaropoulos G, et al
It was originally developed by Metabolic Pharmaceuticals in Australia during the late 1990s as a potential **anti-obesity peptide** that could stimulate fat loss without the growth-promoting or diabetogenic effects of full-length growth hormone
Cagrilintide itself isn't widely available as a standalone Durham Peptides doesn't currently stock it separately which means the blend is the practical route to cagrilintide in the Canadian market, and the price reflects what cagrilintide actually costs to produce at research grade, not a simple two-component sum
Nancy Salbach: nothing to disclose